OBD vs. TRX, COS, C4XD, DDDD, SAR, OKYO, AREC, AOR, POLB, and RLM
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Sareum (SAR), OKYO Pharma (OKYO), Arecor Therapeutics (AREC), AorTech International (AOR), Poolbeg Pharma (POLB), and Realm Therapeutics (RLM). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs. Its Competitors
Oxford BioDynamics (LON:OBD) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
Tissue Regenix Group has a net margin of -3.46% compared to Oxford BioDynamics' net margin of -1,800.32%. Tissue Regenix Group's return on equity of -2.87% beat Oxford BioDynamics' return on equity.
Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Tissue Regenix Group'saverage media sentiment score.
44.3% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are held by institutional investors. 16.8% of Oxford BioDynamics shares are held by insiders. Comparatively, 47.3% of Tissue Regenix Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tissue Regenix Group has higher revenue and earnings than Oxford BioDynamics. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
Summary
Tissue Regenix Group beats Oxford BioDynamics on 8 of the 11 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 7/24/2025 by MarketBeat.com Staff
